Drug resistance remains a major obstacle to prolonging the lives of cancer patients, including those with myeloma and leukemia. Recently, we have become more aware of the influence of the tumor microenvironment on tumor cell survival and growth. The central hypothesis of this application is that the tumor microenvironment provides a sanctuary for subpopulations of tumor cells to evade or circumvent drug-induced cell death and that this represents a form of de novo drug resistance. Furthermore, we believe that this form of de novo drug resistance is a major contributor to the development of minimal residual disease following initial treatment. The subpopulation of cells, or minimal residual disease, that survives initial treatment progresses to acquire complex mechanisms of drug resistance resulting in disease progression that is difficult to overcome. Focusing on hematologic malignancies, mainly multiple myeloma (MM), we propose that the bone marrow microenvironment, which includes extracellular matrices, stromal cells, and soluble factors, protects tumor cells from drug-induced cell death. Our initial work during the past funding period of this grant focused on the physical contact of tumor cells with the extracellular matrix protein, fibronectin (FN), and we coined the term """"""""cell adhesion mediated drug resistance"""""""" (CAM-DR) to describe this phenotype. Recently, we have extended our work to include studies of tumor cell interaction with bone marrow stroma (BMS), and discovered that in addition to drug resistance mediated by physical contact, soluble factors (growth factors, and cytokines) produced by the tumor cell interactions with BMS also contribute to the drug resistant phenotype, thereby deriving the term """"""""environment mediated drug resistance"""""""" or EMDR. In this grant proposal we will capitalize on our previous experience, to elucidate mechanisms of EMDR.
Specific aims of this grant will a) use gene expression profiling to identify novel targets for sensitizing cancer cells residing in the bone marrow microenvironment to chemotherapy;b) examine the contribution of Stat3 pathway in mediating EMDR;and c) investigate the contribution of NF-kB in mediating EMDR using an in vivo mouse model of MM. Preventing or circumventing this form of de novo drug resistance will prevent or delay the emergence of acquired drug resistance by reducing the extent and occurrence of minimal residual disease.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Developmental Therapeutics Study Section (DT)
Program Officer
Forry, Suzanne L
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
H. Lee Moffitt Cancer Center & Research Institute
United States
Zip Code
Lin, J; Lwin, T; Zhao, J-J et al. (2011) Follicular dendritic cell-induced microRNA-mediated upregulation of PRDM1 and downregulation of BCL-6 in non-Hodgkin's B-cell lymphomas. Leukemia 25:145-52
Xiang, Yun; Remily-Wood, Elizabeth R; Oliveira, Vasco et al. (2011) Monitoring a nuclear factor-?B signature of drug resistance in multiple myeloma. Mol Cell Proteomics 10:M110.005520
Remily-Wood, Elizabeth R; Liu, Richard Z; Xiang, Yun et al. (2011) A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancer. Proteomics Clin Appl 5:383-96
Perez, Lia E; Parquet, Nancy; Meads, Mark et al. (2010) Bortezomib restores stroma-mediated APO2L/TRAIL apoptosis resistance in multiple myeloma. Eur J Haematol 84:212-22
Lwin, Tint; Lin, Jianhong; Choi, Yong Sung et al. (2010) Follicular dendritic cell-dependent drug resistance of non-Hodgkin lymphoma involves cell adhesion-mediated Bim down-regulation through induction of microRNA-181a. Blood 116:5228-36
Zhao, Jian-Jun; Lin, Jianhong; Lwin, Tint et al. (2010) microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood 115:2630-9
Meads, Mark B; Li, Zhi-Wei; Dalton, William S (2010) A novel TNF receptor-associated factor 6 binding domain mediates NF-kappa B signaling by the common cytokine receptor beta subunit. J Immunol 185:1606-15
Shain, Kenneth H; Dalton, William S (2009) Environmental-mediated drug resistance: a target for multiple myeloma therapy. Expert Rev Hematol 2:649-62
Yarde, Danielle N; Oliveira, Vasco; Mathews, Linda et al. (2009) Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma. Cancer Res 69:9367-75
Shain, Kenneth H; Yarde, Danielle N; Meads, Mark B et al. (2009) Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Res 69:1009-15

Showing the most recent 10 out of 29 publications